ArticleDrug design, development and therapy2020
Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Improves Spinal Cord Function After Injury in Rats by Activating Autophagy.
Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Repair of spinal cord injury by bone marrow mesenchymal stem cell-derived exosomes: a systematic review and meta-analysis based on rat models.Frontiers in molecular neuroscience · 2024Pooled it
- Therapeutic Effect of Exosomes Derived From Stem Cells in Spinal Cord Injury: A Systematic Review Based on Animal Studies.Frontiers in neurology · 2022Pooled it
- Efficacy of miRNA-modified mesenchymal stem cell extracellular vesicles in spinal cord injury: A systematic review of the literature and network meta-analysis.Frontiers in neuroscience · 2022Pooled it
- Continuous intravenous infusion of human mesenchymal stromal cell-derived small extracellular vesicles in spinal cord injured rat modulates extracellular matrix and has greater therapeutic efficacy than multiple single injections.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Exosomes as regenerative therapeutics for spinal cord injury: mechanisms and clinical prospects.Frontiers in medicine · 2026Review
- Roles for Exosomes from Various Cellular Sources in Spinal Cord Injury.Molecular neurobiology · 2025Review
- BMSCs-derived exosomal AKAP12 alleviates neuronal cell ferroptosis by inhibiting the STAT3 and ERK signaling pathways in spinal cord injury.Journal of molecular medicine (Berlin, Germany) · 2025Article
- The Role of Autophagy in Long-term Effects of Spinal Cord Injury: Does Exosome Change the Autophagy Process and Vice Versa?Advanced pharmaceutical bulletin · 2025Review
- Global trends on exosomes in spinal cord injury: A bibliometric analysis and mini-review.Biomaterials translational · 2025Article
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Spinal Cord Injury.Molecular neurobiology · 2025Review
- Insights into Astrogliosis, Inflammation Processes, and Emerging Treatments by Exosome Therapy and Low-Level Laser Therapy for Spinal Cord Injury: A Systematic Review.Journal of lasers in medical sciences · 2025Review
- Exosome-Loaded Bioscaffolds for Spinal Cord Injuries: A Review.Stem cells international · 2025Review
- BMSC-Derived Exosomes Carrying miR-26a-5p Ameliorate Spinal Cord Injury via Negatively Regulating EZH2 and Activating the BDNF-TrkB-CREB Signaling.Molecular neurobiology · 2024Article
- Exosomes as promising bioactive materials in the treatment of spinal cord injury.Stem cell research & therapy · 2024Review
- The Role of Exosomes from Mesenchymal Stem Cells in Spinal Cord Injury: A Systematic Review.International journal of stem cells · 2024Review
- Enhancing angiogenesis and inhibiting apoptosis: evaluating the therapeutic efficacy of bone marrow mesenchymal stem cell-derived exosomes in a DHEA-induced PCOS mouse model.Journal of ovarian research · 2024Article
- Understanding molecular characteristics of extracellular vesicles derived from different types of mesenchymal stem cells for therapeutic translation.Extracellular vesicle · 2024Article
- Review
- Mesenchymal stem cell-derived exosomes as a new drug carrier for the treatment of spinal cord injury: A review.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal cord injury (SCI) is a global medical problem. The smallest membrane-bound nanovesicles, known as exosomes, have a role in complex intercellular communication systems and can be used directly as therapeutic agents by acting as important paracrine factors. Nevertheless, the use of exosomes derived from BMSCs (BMSC-Exos) to treat SCI has been less, and the specific mechanism has not yet been reported.
methodsBMSC-Exos were characterized by TEM, NTA and Western blot. The effects of BMSC-Exos treatment were compared by SCI in vivo model and a series of in vitro experiments.
resultsBMSC-Exos were found to enhance the expression of autophagy-related proteins LC3IIB and Beclin-1 and enabled autophagosomes formation. After BMSC-Exos treatment, there was marked decline in the level of expression of proapoptotic protein cleaved caspase-3, while that of the antiapoptotic protein Bcl-2 was upregulated.
conclusionBMSC-Exos can attenuate neuronal apoptosis by promoting autophagy and promote the potential efficacy of functional behavior recovery in SCI rats. In summary, these findings expand the theoretical knowledge and forms a realistic route for the future treatment of SCI by BMSC-Exos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.